Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, July 22, 2025
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025
Wednesday, July 16, 2025
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
Monday, July 14, 2025
"URECE" (Dotinurad) Launched in China as a treatment for Gout
Tuesday, July 8, 2025
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment
Monday, June 2, 2025
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan
Wednesday, May 28, 2025
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
Wednesday, May 21, 2025
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
Friday, May 16, 2025
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro
Wednesday, April 30, 2025
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
Friday, April 18, 2025
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union

Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: